JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M501972200 on May 10, 2005

J. Biol. Chem., Vol. 280, Issue 28, 26039-26048, July 15, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
280/28/26039    most recent
M501972200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moog-Lutz, C.
Right arrow Articles by Vigny, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moog-Lutz, C.
Right arrow Articles by Vigny, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin*{boxs}

Christel Moog-Lutz{ddagger}§, Joffrey Degoutin{ddagger}§, Jean Y. Gouzi{ddagger}, Yvelyne Frobert¶, Nicole Brunet-de Carvalho{ddagger}, Jocelyne Bureau{ddagger}, Christophe Créminon¶, and Marc Vigny{ddagger}||

From the {ddagger}INSERM, Unité 706/Université Pierre et Marie Curie, Paris F-75005 and the Service de Pharmacologie et d'Immunologie, Direction de la Recherche Médicale, Commissariat à l'Energie Atomique-Saclay, Gif/Yvette 91191, France

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is transiently expressed in specific regions of the central and peripheral nervous systems, suggesting a role in its normal development and function. The nature of the cognate ligands of ALK in vertebrate is still a matter of debate. We produced a panel of monoclonal antibodies (mAbs) directed against the extracellular domain of the human receptor. Two major species of ALK (220 and 140 kDa) were identified in transfected cells, and the use of our mAbs established that the 140-kDa species results from a cleavage of the 220-kDa form. Two mAbs, in the nM range, induced the differentiation of PC12 cells transiently transfected with ALK. In human embryonic kidney 293 cells stably expressing ALK, these two mAbs strongly activated the receptor and subsequently the mitogen-activated protein kinase pathway. We further showed for the first time that activation of ALK also resulted in a specific activation of STAT3. In contrast, other mAbs presented the characteristics of blocking antibodies. Finally, in these cell systems, a mitogenic form of pleiotrophin, a proposed ligand of ALK, failed to activate this receptor. Thus, in the absence of clearly established ligand(s) in vertebrates, the availability of mAbs allowing the activation or the inhibition of the receptor will be essential for a better understanding of the biological roles of ALK.


Received for publication, February 22, 2005 , and in revised form, May 6, 2005.

* This work was supported in part by institutional funding from INSERM and Université Paris 6 as well as by grants from the Association pour la Recherche sur le Cancer and the Association Française contre les Myopathies. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

{boxs} The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1 and S2.

§ These authors contributed equally to this work.

|| To whom correspondence should be addressed: INSERM Unité 706/UPMC, Institut du Fer à Moulin, 17 rue du Fer à Moulin, Paris F-75005, France. E-mail: vigny{at}fer-a-moulin.inserm.fr.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
H. M. Amin and R. Lai
Pathobiology of ALK+ anaplastic large-cell lymphoma
Blood, October 1, 2007; 110(7): 2259 - 2267.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Perez-Pinera, W. Zhang, Y. Chang, J. A. Vega, and T. F. Deuel
Anaplastic Lymphoma Kinase Is Activated Through the Pleiotrophin/Receptor Protein-tyrosine Phosphatase beta/{zeta} Signaling Pathway: AN ALTERNATIVE MECHANISM OF RECEPTOR TYROSINE KINASE ACTIVATION
J. Biol. Chem., September 28, 2007; 282(39): 28683 - 28690.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Mourali, A. Benard, F. C. Lourenco, C. Monnet, C. Greenland, C. Moog-Lutz, C. Racaud-Sultan, D. Gonzalez-Dunia, M. Vigny, P. Mehlen, et al.
Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage.
Mol. Cell. Biol., August 1, 2006; 26(16): 6209 - 6222.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
J. Y. Gouzi, C. Moog-Lutz, M. Vigny, and N. Brunet-de Carvalho
Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells
J. Cell Sci., December 15, 2005; 118(24): 5811 - 5823.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.